» Articles » PMID: 32435699

Spatial Immune Profiling of the Colorectal Tumor Microenvironment Predicts Good Outcome in Stage II Patients

Overview
Journal NPJ Digit Med
Date 2020 May 22
PMID 32435699
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Cellular subpopulations within the colorectal tumor microenvironment (TME) include CD3 and CD8 lymphocytes, CD68 and CD163 macrophages, and tumor buds (TBs), all of which have known prognostic significance in stage II colorectal cancer. However, the prognostic relevance of their spatial interactions remains unknown. Here, by applying automated image analysis and machine learning approaches, we evaluate the prognostic significance of these cellular subpopulations and their spatial interactions. Resultant data, from a training cohort retrospectively collated from Edinburgh, UK hospitals ( = 113), were used to create a combinatorial prognostic model, which identified a subpopulation of patients who exhibit 100% survival over a 5-year follow-up period. The combinatorial model integrated lymphocytic infiltration, the number of lymphocytes within 50-μm proximity to TBs, and the CD68/CD163 macrophage ratio. This finding was confirmed on an independent validation cohort, which included patients treated in Japan and Scotland ( = 117). This work shows that by analyzing multiple cellular subpopulations from the complex TME, it is possible to identify patients for whom surgical resection alone may be curative.

Citing Articles

Interaction of human gut microbiota and local immune system in progression of colorectal adenoma (MIMICA-1): a protocol for a prospective, observational cohort study.

Valciukiene J, Lastauskiene E, Laurinaviciene A, Jakubauskas M, Kryzauskas M, Valkiuniene R Front Oncol. 2025; 14():1495635.

PMID: 39834942 PMC: 11743970. DOI: 10.3389/fonc.2024.1495635.


Advancing precision medicine: the transformative role of artificial intelligence in immunogenomics, radiomics, and pathomics for biomarker discovery and immunotherapy optimization.

Chang L, Liu J, Zhu J, Guo S, Wang Y, Zhou Z Cancer Biol Med. 2025; 22(1).

PMID: 39749734 PMC: 11795263. DOI: 10.20892/j.issn.2095-3941.2024.0376.


Combining immunoscore and tumor budding in colon cancer: an insightful prognostication based on the tumor-host interface.

Haddad T, Bokhorst J, Berger M, Dobbelsteen L, Simmer F, Ciompi F J Transl Med. 2024; 22(1):1090.

PMID: 39623479 PMC: 11610196. DOI: 10.1186/s12967-024-05818-z.


The evolution of immune profiling: will there be a role for nanoparticles?.

Eremina O, Vazquez C, Larson K, Mouchawar A, Fernando A, Zavaleta C Nanoscale Horiz. 2024; 9(11):1896-1924.

PMID: 39254004 PMC: 11887860. DOI: 10.1039/d4nh00279b.


Signaling by Type I Interferons in Immune Cells: Disease Consequences.

Zannikou M, Fish E, Platanias L Cancers (Basel). 2024; 16(8).

PMID: 38672681 PMC: 11049350. DOI: 10.3390/cancers16081600.


References
1.
Li S, Xu F, Zhang J, Wang L, Zheng Y, Wu X . Tumor-associated macrophages remodeling EMT and predicting survival in colorectal carcinoma. Oncoimmunology. 2018; 7(2):e1380765. PMC: 5798198. DOI: 10.1080/2162402X.2017.1380765. View

2.
Zlobec I, Lugli A . Tumour budding in colorectal cancer: molecular rationale for clinical translation. Nat Rev Cancer. 2018; 18(4):203-204. DOI: 10.1038/nrc.2018.1. View

3.
Ko Y, Pyo J . Clinicopathological significance and prognostic role of tumor-infiltrating lymphocytes in colorectal cancer. Int J Biol Markers. 2019; 34(2):132-138. DOI: 10.1177/1724600818817320. View

4.
Hanahan D, Coussens L . Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012; 21(3):309-22. DOI: 10.1016/j.ccr.2012.02.022. View

5.
De Smedt L, Palmans S, Andel D, Govaere O, Boeckx B, Smeets D . Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching. Br J Cancer. 2016; 116(1):58-65. PMC: 5220148. DOI: 10.1038/bjc.2016.382. View